BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38272991)

  • 21. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
    Terwijn M; Kelder A; Snel AN; Rutten AP; Scholten WJ; Oussoren YJ; Van De Loosdrecht AA; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Int J Lab Hematol; 2012 Aug; 34(4):432-41. PubMed ID: 22471741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
    Shang L; Cai X; Sun W; Cheng Q; Mi Y
    Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
    Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
    Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
    Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
    Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome.
    Oliveira E; Costa ES; Ciudad J; Gaipa G; Sedek Ł; Barrena S; Szczepanski T; Buracchi C; Silvestri D; Siqueira PFR; Mello FV; Torres RC; Oliveira LMR; Fay-Neves IVC; Sonneveld E; van der Velden VHJ; Mejstrikova E; Ribera JM; Conter V; Schrappe M; van Dongen JJM; Land MGP; Orfao A;
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Zuna J; Moericke A; Arens M; Koehler R; Panzer-Grümayer R; Bartram CR; Fischer S; Fronkova E; Zaliova M; Schrauder A; Stanulla M; Zimmermann M; Trka J; Stary J; Attarbaschi A; Mann G; Schrappe M; Cario G
    Br J Haematol; 2016 Jun; 173(5):742-8. PubMed ID: 26913693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.
    Óskarsson JÞ; Rögnvaldsson S; Thorsteinsdottir S; Aspelund T; Gunnarsson SB; Hákonardóttir GK; Sigurðardóttir GÁ; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Sigurðsson JK; Eyþórsson E; Jónsson Á; Viðarsson B; Önundarson PT; Agnarsson BA; Pálmason R; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Harding S; Flores-Montero J; Orfao A; Durie BGM; Love TJ; Kristinsson SY
    Blood Cancer J; 2023 Dec; 13(1):177. PubMed ID: 38040702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
    Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
    Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.
    Hanekamp D; Tettero JM; Ossenkoppele GJ; Kelder A; Cloos J; Schuurhuis GJ
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
    Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
    Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
    Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.